Looking beyond histological healingin ulcerative colitis: Towards the establishment of a molecular signature for quiescent but progressive disease

Gut

Volumn 62, Issue 7, 2013, Pages 959-960

  Chamaillard, Mathias ^a,b,c,d   Chevaux, Jean Baptiste ^d   Peyrin Biroulet, Laurent ^d  

^a UNIV LILLE   (France)

^b INSTITUT PASTEUR DE LILLE   (France)

^c INSERM U1019   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN S 100; TRANSCRIPTOME;

DISEASE ACTIVITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; HISTOLOGY; HUMAN; NOTE; PRIORITY JOURNAL; PROGNOSIS; QUIESCENT DISEASE; RELAPSE; REMISSION; ULCERATIVE COLITIS; COLON; COLORECTAL CANCER; FEMALE; GENETICS; INTESTINE MUCOSA; MALE; METABOLISM; MUCOSAL REPAIR;

COLORECTAL CANCER; MUCOSAL REPAIR; ULCERATIVE COLITIS;

COLITIS, ULCERATIVE; COLON; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; TRANSCRIPTOME;

EID: 84878767338     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-303765     Document Type: Note

References (11)

1. Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis 2012;18:1356-63.
2. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8.
3. Peyrin-Biroulet L, Ferrante M, Magro F, et al. Results from the 2nd scientific workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis 2011;5:477-83.
4. Travis SP, Higgins PD, Orchard T, et al. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011;34:113-24.
5. Planell N, Lozano JJ, Mora-Buch R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations. Gut 2013;62:967-76.
6. Arijs I, De Hertogh G, Lemaire K, et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS ONE 2009;4:e7984.
7. Peyrin-Biroulet L, Beisner J, Wang G, et al. Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 2010;107:8772-7.
8. Scanlan PD, Shanahan F, O'Mahony C, et al. Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J Clin Microbiol 2006;44:3980-8. (Pubitemid 44737239)
9. Seksik P, Rigottier-Gois L, Gramet G, et al. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 2003;52:237-42. (Pubitemid 36115065)
10. Sokol H, Lepage P, Seksik P, et al. Molecular comparison of dominant microbiota associated with injured versus healthy mucosa in ulcerative colitis. Gut 2007;56:152-4. (Pubitemid 46044904)
11. Shen C, de Hertogh G, Bullens DM, et al. Remission-inducing effect of anti-TNF monoclonal antibody in TNBS colitis: mechanisms beyond neutralization? Inflamm Bowel Dis 2007;13:308-16. (Pubitemid 46465912)